Trevena's Play Out Of Pain Space Fails In Phase IIb

Trevena Inc.'s future as more than just a one-trick pony is in question following the company's announcement it is discontinuing development of acute heart failure therapy, TRV027, after the drug failed to meet primary or secondary endpoints in a Phase IIb study.